Close cooperation with Health Technology Assessment expertise is crucial for implementation and ultimately reimbursement of innovations in oncology

The Organisation of European Cancer Institutes OECI working group on Health Economics and Cost Benefit in Oncology suggests four actions that are needed to improve alignment and integration between clinicians, researchers, and Health Technology Assessment (HTA) experts and agencies: 1) HTA expertise...

Full description

Saved in:
Bibliographic Details
Published in:Ecancermedicalscience 2016-10, Vol.10, p.686-686
Main Authors: van Harten, W H, Retèl, V P
Format: Article
Language:English
Subjects:
Cancer
Cooperation
Decision making
Drugs
GNP
Gross National Product
Health economics
Health services
Insurance coverage
Oncology
Out of pocket costs
Pharmaceutical industry
Policy
Researchers
Sustainability
Trends
Working groups
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c424t-206d7a0953f1a4f6df164b481546e5e46c81688e2c6da6a84555169214d683f13
cites
container_end_page 686
container_issue
container_start_page 686
container_title Ecancermedicalscience
container_volume 10
creator van Harten, W H
Retèl, V P
description The Organisation of European Cancer Institutes OECI working group on Health Economics and Cost Benefit in Oncology suggests four actions that are needed to improve alignment and integration between clinicians, researchers, and Health Technology Assessment (HTA) experts and agencies: 1) HTA expertise is necessary close to or within the comprehensive cancer centres (CCC); 2) HTA expertise should be physically present throughout the translational research process; 3) Appropriate knowledge is necessary within the research staff; 4) Close cooperation between translational researchers, clinicians, and health economists guarantees clinical ownership. Fulfilling these conditions may help the translational research field in oncology to interact with agencies and efficiently move innovative technologies through the translational research stages into that of implementation and diffusion. This brings innovative treatments faster to the patient with a greater chance of reimbursement.
doi_str_mv 10.3332/ecancer.2016.686
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5130332</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1952708601</sourcerecordid><originalsourceid>FETCH-LOGICAL-c424t-206d7a0953f1a4f6df164b481546e5e46c81688e2c6da6a84555169214d683f13</originalsourceid><addsrcrecordid>eNpdkU9vEzEQxS0EoqVw54Qsceklqe21J94LUhUVilSpl3K2HO9s48prB3u3JZ-DL4zzh6pwmpH8ezNv_Aj5yNm8aRpxgc5Gh3kuGIc5aHhFTvlCyRkAU69f9CfkXSkPjAFvhXpLTsSibSVIcUp-L0MqSF1KG8x29CnSJz-u6TXaUMsdunVMId1v6WUpWMqAcaT4q8KjrzpfqMuT8zbQPmXqh03AHXKYZGNHpzD6wY4YtjSjH1ZTLnuCpp76GNPjHi21pym6_ar35E1vQ8EPx3pGfny9ultez25uv31fXt7MnBRynAkG3cKyVjU9t7KHrucgV1JzJQEVSnCag9YoHHQWrJZKKQ6t4LIDXTXNGflymLuZVgN2rrrKNphNrobz1iTrzb8v0a_NfXo0ijesfn8dcH4ckNPPCctoBl8chmAjpqkYrhUXbd2rK_r5P_QhTTnW8wxvlVgwDWzniB0ol1MpGftnM5yZXeLmmLjZJW5q4lXy6eURz4K_ETd_AAw6rPE</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1952708601</pqid></control><display><type>article</type><title>Close cooperation with Health Technology Assessment expertise is crucial for implementation and ultimately reimbursement of innovations in oncology</title><source>Publicly Available Content Database</source><source>PubMed Central</source><creator>van Harten, W H ; Retèl, V P</creator><creatorcontrib>van Harten, W H ; Retèl, V P</creatorcontrib><description>The Organisation of European Cancer Institutes OECI working group on Health Economics and Cost Benefit in Oncology suggests four actions that are needed to improve alignment and integration between clinicians, researchers, and Health Technology Assessment (HTA) experts and agencies: 1) HTA expertise is necessary close to or within the comprehensive cancer centres (CCC); 2) HTA expertise should be physically present throughout the translational research process; 3) Appropriate knowledge is necessary within the research staff; 4) Close cooperation between translational researchers, clinicians, and health economists guarantees clinical ownership. Fulfilling these conditions may help the translational research field in oncology to interact with agencies and efficiently move innovative technologies through the translational research stages into that of implementation and diffusion. This brings innovative treatments faster to the patient with a greater chance of reimbursement.</description><identifier>ISSN: 1754-6605</identifier><identifier>EISSN: 1754-6605</identifier><identifier>DOI: 10.3332/ecancer.2016.686</identifier><identifier>PMID: 27994642</identifier><language>eng</language><publisher>England: Cancer Intelligence</publisher><subject>Cancer ; Cooperation ; Decision making ; Drugs ; GNP ; Gross National Product ; Health economics ; Health services ; Insurance coverage ; Oncology ; Out of pocket costs ; Pharmaceutical industry ; Policy ; Researchers ; Sustainability ; Trends ; Working groups</subject><ispartof>Ecancermedicalscience, 2016-10, Vol.10, p.686-686</ispartof><rights>the authors; licensee ecancermedicalscience. 2016. This work is licensed under the Creative Commons Attribution License (https://creativecommons.org/licenses/by/3.0/) (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>the authors; licensee ecancermedicalscience. 2016</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c424t-206d7a0953f1a4f6df164b481546e5e46c81688e2c6da6a84555169214d683f13</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/1952708601/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/1952708601?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25753,27924,27925,37012,37013,44590,53791,53793,75126</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27994642$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>van Harten, W H</creatorcontrib><creatorcontrib>Retèl, V P</creatorcontrib><title>Close cooperation with Health Technology Assessment expertise is crucial for implementation and ultimately reimbursement of innovations in oncology</title><title>Ecancermedicalscience</title><addtitle>Ecancermedicalscience</addtitle><description>The Organisation of European Cancer Institutes OECI working group on Health Economics and Cost Benefit in Oncology suggests four actions that are needed to improve alignment and integration between clinicians, researchers, and Health Technology Assessment (HTA) experts and agencies: 1) HTA expertise is necessary close to or within the comprehensive cancer centres (CCC); 2) HTA expertise should be physically present throughout the translational research process; 3) Appropriate knowledge is necessary within the research staff; 4) Close cooperation between translational researchers, clinicians, and health economists guarantees clinical ownership. Fulfilling these conditions may help the translational research field in oncology to interact with agencies and efficiently move innovative technologies through the translational research stages into that of implementation and diffusion. This brings innovative treatments faster to the patient with a greater chance of reimbursement.</description><subject>Cancer</subject><subject>Cooperation</subject><subject>Decision making</subject><subject>Drugs</subject><subject>GNP</subject><subject>Gross National Product</subject><subject>Health economics</subject><subject>Health services</subject><subject>Insurance coverage</subject><subject>Oncology</subject><subject>Out of pocket costs</subject><subject>Pharmaceutical industry</subject><subject>Policy</subject><subject>Researchers</subject><subject>Sustainability</subject><subject>Trends</subject><subject>Working groups</subject><issn>1754-6605</issn><issn>1754-6605</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><recordid>eNpdkU9vEzEQxS0EoqVw54Qsceklqe21J94LUhUVilSpl3K2HO9s48prB3u3JZ-DL4zzh6pwmpH8ezNv_Aj5yNm8aRpxgc5Gh3kuGIc5aHhFTvlCyRkAU69f9CfkXSkPjAFvhXpLTsSibSVIcUp-L0MqSF1KG8x29CnSJz-u6TXaUMsdunVMId1v6WUpWMqAcaT4q8KjrzpfqMuT8zbQPmXqh03AHXKYZGNHpzD6wY4YtjSjH1ZTLnuCpp76GNPjHi21pym6_ar35E1vQ8EPx3pGfny9ultez25uv31fXt7MnBRynAkG3cKyVjU9t7KHrucgV1JzJQEVSnCag9YoHHQWrJZKKQ6t4LIDXTXNGflymLuZVgN2rrrKNphNrobz1iTrzb8v0a_NfXo0ijesfn8dcH4ckNPPCctoBl8chmAjpqkYrhUXbd2rK_r5P_QhTTnW8wxvlVgwDWzniB0ol1MpGftnM5yZXeLmmLjZJW5q4lXy6eURz4K_ETd_AAw6rPE</recordid><startdate>20161028</startdate><enddate>20161028</enddate><creator>van Harten, W H</creator><creator>Retèl, V P</creator><general>Cancer Intelligence</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20161028</creationdate><title>Close cooperation with Health Technology Assessment expertise is crucial for implementation and ultimately reimbursement of innovations in oncology</title><author>van Harten, W H ; Retèl, V P</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c424t-206d7a0953f1a4f6df164b481546e5e46c81688e2c6da6a84555169214d683f13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Cancer</topic><topic>Cooperation</topic><topic>Decision making</topic><topic>Drugs</topic><topic>GNP</topic><topic>Gross National Product</topic><topic>Health economics</topic><topic>Health services</topic><topic>Insurance coverage</topic><topic>Oncology</topic><topic>Out of pocket costs</topic><topic>Pharmaceutical industry</topic><topic>Policy</topic><topic>Researchers</topic><topic>Sustainability</topic><topic>Trends</topic><topic>Working groups</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>van Harten, W H</creatorcontrib><creatorcontrib>Retèl, V P</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Ecancermedicalscience</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>van Harten, W H</au><au>Retèl, V P</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Close cooperation with Health Technology Assessment expertise is crucial for implementation and ultimately reimbursement of innovations in oncology</atitle><jtitle>Ecancermedicalscience</jtitle><addtitle>Ecancermedicalscience</addtitle><date>2016-10-28</date><risdate>2016</risdate><volume>10</volume><spage>686</spage><epage>686</epage><pages>686-686</pages><issn>1754-6605</issn><eissn>1754-6605</eissn><abstract>The Organisation of European Cancer Institutes OECI working group on Health Economics and Cost Benefit in Oncology suggests four actions that are needed to improve alignment and integration between clinicians, researchers, and Health Technology Assessment (HTA) experts and agencies: 1) HTA expertise is necessary close to or within the comprehensive cancer centres (CCC); 2) HTA expertise should be physically present throughout the translational research process; 3) Appropriate knowledge is necessary within the research staff; 4) Close cooperation between translational researchers, clinicians, and health economists guarantees clinical ownership. Fulfilling these conditions may help the translational research field in oncology to interact with agencies and efficiently move innovative technologies through the translational research stages into that of implementation and diffusion. This brings innovative treatments faster to the patient with a greater chance of reimbursement.</abstract><cop>England</cop><pub>Cancer Intelligence</pub><pmid>27994642</pmid><doi>10.3332/ecancer.2016.686</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1754-6605
ispartof Ecancermedicalscience, 2016-10, Vol.10, p.686-686
issn 1754-6605
1754-6605
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5130332
source Publicly Available Content Database; PubMed Central
subjects Cancer
Cooperation
Decision making
Drugs
GNP
Gross National Product
Health economics
Health services
Insurance coverage
Oncology
Out of pocket costs
Pharmaceutical industry
Policy
Researchers
Sustainability
Trends
Working groups
title Close cooperation with Health Technology Assessment expertise is crucial for implementation and ultimately reimbursement of innovations in oncology
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-03T09%3A01%3A57IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Close%20cooperation%20with%20Health%20Technology%20Assessment%20expertise%20is%20crucial%20for%20implementation%20and%20ultimately%20reimbursement%20of%20innovations%20in%20oncology&rft.jtitle=Ecancermedicalscience&rft.au=van%20Harten,%20W%20H&rft.date=2016-10-28&rft.volume=10&rft.spage=686&rft.epage=686&rft.pages=686-686&rft.issn=1754-6605&rft.eissn=1754-6605&rft_id=info:doi/10.3332/ecancer.2016.686&rft_dat=%3Cproquest_pubme%3E1952708601%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c424t-206d7a0953f1a4f6df164b481546e5e46c81688e2c6da6a84555169214d683f13%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1952708601&rft_id=info:pmid/27994642&rfr_iscdi=true